Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We are passionate about designing new immunology focused medicines that target the most critical elements of the tumor immunity axis to improve the lives of patients with difficult-to-treat diseases. We have a deep pipeline of investigational medicines that we are efficiently advancing in preclinical studies and in intelligently-designed, rigorously-conducted clinical trials....
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Mar 21, 2023
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Mar 14, 2023
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Feb 21, 2023
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal